Veozah Approved for Moderate to Severe Vasomotor Symptoms Due to Menopause
Veozah is an oral neurokinin 3 (NK3) receptor antagonist.
Veozah is an oral neurokinin 3 (NK3) receptor antagonist.
Researchers investigated pain experiences among women with noncommunicable diseases across different regions and age groups.
CMS investigates 2 hospitals for EMTALA violations related to abortion care for a pregnancy-related emergency.
The safety and efficacy of fezolinetant in the treatment of menopause-related vasomotor symptoms were assessed.
Researchers sought to determine the extent in which sex, age at menopause, and hormone therapy use are associated with regional tau at a given level of Aβ — both measured with PET.
Researchers assessed the long-term efect of denosumab on bone microarchitecture.
Investigators searched publication databases from inception through to July 2021 for studies about loneliness in the perinatal setting for this meta-synthesis.
If approved, Opill would be the first daily oral contraceptive pill available without a prescription.
Research on the effect of NSAID use, including aspirin, on bone health has resulted in conflicting results.
Researchers studied the link between plant-based dietary patterns and osteoporosis among older adults.